NCT04228172Completed
Genotypic Influences on Network Progression in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
In this longitudinal study, the investigators will follow Parkinson's disease (PD) patients with and without glucocerebrosidase (GBA) mutations. The investigators hypothesize that the rate of increase in brain network activity over time (network progression rate) is faster in patients with GBA gene mutations.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 17 (actual)
- First submitted
- 7 Jan 2020
- Start date
- 24 Feb 2020
- Primary completion date
- 7 Mar 2026
- Lead sponsor
- Northwell Health
- Diseases
- Parkinson disease
- NCT number
- NCT04228172
What you commit to
- Study type: Observational
- Participants enrolled: 17
- From 24 Feb 2020 to the primary completion date, 7 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of known causative factors such as encephalitis or neuroleptic treatment
- Patients with dementia (defined as Mini-Mental Status Exam score \<24 or a Telephone Interview for Cognitive Status score \<26)
- Patients with history of stroke, head injury, high intracranial pressure or severe headaches
- Psychiatric disorder, including a history of major depression in the past 36 months
Other
- Subjects with pathogenic mutations in LRRK2 related PD mutations (subjects with variants of uncertain significance (VUS) are eligible
- Atypical parkinsonian features including oculomotor abnormalities, incontinence, ataxia, sensory loss, or pyramidal signs
- Known structural brain lesions
- Pregnant or breastfeeding women (female subjects of child-bearing potential will be screened for pregnancy before imaging).
Who the study is looking for
- Diagnosis of PD made according to United Kingdom (UK) Parkinson's Disease Society Brain Bank Criteria
- Ability to provide written informed consent
- Age 40-75
- Stable dose of antiparkinsonian medication for \>1 month prior to study entry
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Feinstein Institutes for Medical Research Coordinator of this site? Confirm its status | Manhasset | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.